The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Uses of MRD in patients with multiple myeloma
Rafael Fonseca
• 1 Jun 2018
In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be used in the treatment of multiple myeloma (MM), including how his practice uses MRD. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
